A Trump proposal to link U.S. prescription-drug prices to prices in other countries drew immediate, public opposition from large drug companies.
The five largest drug makers have declined invitations to meet with the President A manufacturing-industry lobbying group produced an ad criticizing the proposal. The group claims the proposal would stifle drug innovation, relying on "price-setting schemes manipulated by foreign governments have no place in our economy."
Trump said he would drop the order if the industry comes up with a better idea by Aug. 24. "We may not need to implement the fourth executive order, which is a very tough order for them," he said.